Even in the case of uncomplicated infections, the body prepares itself early on for the possibility of a more severe course.

The real-world safety profile of tisagenlecleucel appears to be more favourable than that reported in the JULIET study, which led to its FDA approval.

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with ...

The bioenergetic requirements of muscle stem cells (satellite cells) during homeostasis and regeneration remain ill-defined. Here, genetics combined with multi-omics analyses reveal an essential role ...

Response to humanized defucosylated anti-CCR4 antibody (KW-0761) in a representative patient with acute-type adult T-cell leukemia–lymphoma. The time course of lymphocytes and adult T-cell ...

Our blood consists of many cell types that develop through different stages from a precursor type -- the blood stem cell. An international research team has now investigated the developmental pathways ...

U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and EMA marketing authorizations ...

anti-CD7 CAR-T cell therapy for pediatric and adult patients with relapsed or refractory (R/R) T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma (T-ALL/LBL). "The data we have ...